Event Details
We are pleased to announce details of our next OBN C-Suite Breakfast Discussion, kindly hosted on 5 March by New England Biolabs Lyophilization Sciences at their recently opened site on Milton Park, Oxfordshire.
Speakers on the day will be presenting their expert insight on how UK based R&D SME's in the life sciences sector can 'Penetrate the US Market'.
Through keynotes and a moderated round-table discussion, we aim to help share a greater understanding of the US healthcare sector, how to validate technologies and discuss why developing the right partnering strategies are an essential component to support successful growth.
Programme:
08.30 Guest arrival, breakfast and networking
09.00 Welcome by OBN & Kiran Gulati, Director of New England Biolabs Lyophilization Sciences
09.10 Keynote one: Laurie Spicer, Director of US Expansion at Foothold America
09.20 Keynote two: Barney Balmforth, Co-Founder & CEO at Biofidelity
09.30 Round table discussion between all guests
10.30 Event close
Event format: OBN's round table C-Suite Discussions are designed exclusively for senior leaders (C-Suite or equivalent) from life sciences organisations, whether R&D or those involved in providing critical support services to the industry. The purpose of these events is to generate some interesting, useful, high-level and boundary pushing discussion and debate, that creates some practical thought-leadership output.
Please note that places are limited and will be offered on an approval only basis. Complimentary tickets available for OBN Members & Academics, non-OBN Member tickets available at ยฃ75.00 plus VAT.
About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and subsidiaries located in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore, South Korea and the UK. For more information about New England Biolabs visit www.neb.com.